First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

By A. Balar, D. Castellano, P. O’Donnell, P. Grivas, J. Vuky, T. Powles, E. Plimack, N. Hahn, R. de Wit, Lei Pang and 5 more. The Lancet Oncology, 2017

1,143 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/6e307b37b21370da89638916c790b8316a776224

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Pandey
2. P. Kharel
3. A. Chandra
4. R. Garje
5. R. Vaddepally

Citations in the corpus

• European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. (2020, neutral): “In addition, the role of immunotherapy has been evaluated in the first-line setting for cisplatin-ineligible UTUC patients, but limited data on pembrolizumab and atezolizumab are available in the literature [201,202].”
• Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “On the same day, it was also approved as first-line therapy for unresectable or metastatic urothelial cancer patients who are ineligible for cisplatin-containing chemotherapy based on the increased ORR noted in Keynote-052 trial [61] (Category 2A).”